Bioanalytical Systems, Inc. to Host Third Quarter Conference Call Tuesday, August 12.Business Editors/Health/Medical Writers WEST LAFAYETTE West Lafayette, city (1990 pop. 25,907), Tippecanoe co., W Ind., a suburb of Lafayette, on the Wabash River; inc. 1924. A primarily residential city, it is the seat of Purdue Univ. , Ind.--(BUSINESS WIRE)--Aug. 7, 2003 Bioanalytical Systems (Nasdaq:BASI) announced today that the company will host a conference call on Tuesday, August 12 to discuss its third quarter 2003 financial results for the period ended June 30, 2003. A press release announcing the results will be released prior to the market opening at 7:30 a.m. EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT on that day. Peter Kissinger, Chairman and Chief Executive Officer, Doug Wieten, Chief Financial Officer, and Michael Silvon, VP - Planning and Development, will host the call and be available to answer questions. To participate, please dial the following teleconferencing number five minutes prior to the scheduled conference time.
Date: Tuesday, August 12, 2003
Time: 9:00 a.m. Eastern Time
8:00 a.m. Central Time
7:00 a.m. Mountain Time
6:00 a.m. Pacific Time
Dial-In Number: 800-275-3939 (Domestic)
1-973-409-9259 (International)
Also, a live Webcast of the conference call will be available at
www.bioanalytical.com.
For those unable to participate there will be a replay available from Tuesday, August 12 at 11:00 a.m. EDT, through 11:50 p.m. EDT on Thursday August 21, 2003. To listen to the replay, please dial:
Domestic: 877-519-4471
International: 1-973-341-3080
Replay Pin Code: 4097086
A replay of the Webcast will also be available at
www.bioanalytical.com.
In business for nearly 30 years, BASi is a knowledge-based business whose research team has been recognized for its contributions to understanding disease. BASi helps many of the top 25 pharmaceutical companies make peoples' lives better by bringing to market several billion dollars in new drugs for the treatment of central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency , diabetes, osteoporosis, HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and other diseases. BASi is also an industry leader in systems for monitoring in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. biochemistry and physiology. Clients use these systems in new drug development, toxicology toxicology, study of poisons, or toxins, from the standpoint of detection, isolation, identification, and determination of their effects on the human body. Toxicology may be considered the branch of pharmacology devoted to the study of the poisonous effects of drugs. , and in cancer, addiction and behavioral research. Visit www.bioanalytical.com and www.culex Culex /Cu·lex/ (ku´leks) a genus of mosquitoes found throughout the world, many species of which are vectors of disease-producing organisms. Cu·lex n. .net for more about BASi. This release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the development of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion